Comparative analysis of plasma 17-hydroxyprogesterone and cortisol responses to ACTH in patients with various adrenal tumors before and after unilateral adrenalectomy
Patients with non-hyperfunctioning adrenal adenomas often have an increased plasma 17-hydroxyprogesterone response to ACTH stimulation. The effects of adrenal surgery on this abnormality have rarely been investigated. One hundred and sixty-one patients with unilateral adrenal tumors (non-hyperfunctioning adenomas, 78; cortisol-producing adenomas, 8; aldosteroneproducing adenomas, 37; adrenal cysts, 12; pheochromocytomas, 26) were studied. Patients before and after adrenal surgery as well as 60 healthy subjects underwent an ACTH stimulation test using 2 mg synthetic ACTH1-24 (Cortrosyn Depot, Organon). Basal and ACTH-stimulated plasma 17- hydroxyprogesterone and cortisol concentrations are reported. Before adrenal surgery, the basal plasma 17-hydroxyprogesterone concentrations were normal in patients with all types of tumors. However, the ACTH-stimulated plasma 17-hydroxyprogesterone levels were abnormally increased in 53% and 31% of patients with non-hyperfunctioning adenomas and aldosterone-producing adenomas, respectively. In addition, a few patients with adrenal cysts and pheochromocytomas also showed an increased ACTH-stimulated 17- hydroxyprogesterone response. After unilateral adrenalectomy, this hormonal abnormality disappeared in most, although not all patients with adrenal tumors. In patients with non-hyperfunctioning adrenal tumors, ACTH-stimulated plasma 17-hydroxyprogesterone and cortisol concentrations significantly correlated with the size of the tumors. These results firmly indicate that the tumoral mass itself may be responsible for the increased plasma 17-hydroxyprogesterone and cortisol responses after ACTH stimulation in patients with non-hyperfunctioning and hyperfunctioning adrenal adenomas.
Key-wordsAdrenal adrenal tumors 17-hydroxyprogesterone response to ACTH 21-hydroxylase Cushing’s syndrome Conn’s syndrome pheochromocytoma
Unable to display preview. Download preview PDF.
- 1.Jockenhövel F., Kuck W., Hauffa B., Reinhardt W., Benker G., Lederbogen S., Olbricht T., Reinwein D. Conservative and surgical management of incidentally discovered adrenal tumors (incidentalomas). Endocrinol. Invest. 1992, 15: 331–337.Google Scholar
- 2.Turton D.B., O’Brian J.T., Shakir K.M.M. Incidental adrenal nodules: Association with exaggerated 17-hydroxyprogesterone response to adrenocorticotropic hormone. Endocrinol. Invest. 1992, 15: 789–796.Google Scholar
- 11.Sartorio A., Conti A., Ferrero S., Giambona S., Re T., Passini E., Ambrosi B. Evaluation of markers of bone and collagen turnover in patients with active and preclinical Cushing’s syndrome and in patients with adrenal incidentaloma. Eur. J. Endocrinol. 1998, 138: 146–152.PubMedCrossRefGoogle Scholar
- 19.Nagasaka S., Kubota K., Motegi T., Hayashi E., Ohta M., Takahashi T., Iwasaki Y., Koike M., Nishikawa T., Sasano H., Murakami T. A case of silent 21-hydroxylase deficiency with persistent adrenal insufficiency after removal of an adrenal incidentaloma. Clin. Endocrinol. 1996, 44: 111–116.CrossRefGoogle Scholar